291 related articles for article (PubMed ID: 36768484)
1. Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer's Disease and Other Tauopathies.
Altendorf T; Gering I; Santiago-Schübel B; Aghabashlou Saisan S; Tamgüney G; Tusche M; Honold D; Schemmert S; Hoyer W; Mohrlüder J; Willbold D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768484
[TBL] [Abstract][Full Text] [Related]
2. Mirror-Image Phage Display for the Selection of D-Amino Acid Peptide Ligands as Potential Therapeutics.
Malhis M; Funke SA
Curr Protoc; 2024 Feb; 4(2):e957. PubMed ID: 38372457
[TBL] [Abstract][Full Text] [Related]
3. Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display.
Malhis M; Kaniyappan S; Aillaud I; Chandupatla RR; Ramirez LM; Zweckstetter M; Horn AHC; Mandelkow E; Sticht H; Funke SA
Chembiochem; 2021 Nov; 22(21):3049-3059. PubMed ID: 34375027
[TBL] [Abstract][Full Text] [Related]
4. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
5. Structure-based inhibitors halt prion-like seeding by Alzheimer's disease-and tauopathy-derived brain tissue samples.
Seidler PM; Boyer DR; Murray KA; Yang TP; Bentzel M; Sawaya MR; Rosenberg G; Cascio D; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Eisenberg DS
J Biol Chem; 2019 Nov; 294(44):16451-16464. PubMed ID: 31537646
[TBL] [Abstract][Full Text] [Related]
6. Assembly of recombinant tau into filaments identical to those of Alzheimer's disease and chronic traumatic encephalopathy.
Lövestam S; Koh FA; van Knippenberg B; Kotecha A; Murzin AG; Goedert M; Scheres SHW
Elife; 2022 Mar; 11():. PubMed ID: 35244536
[TBL] [Abstract][Full Text] [Related]
7. Amyloidogenesis of Tau protein.
Nizynski B; Dzwolak W; Nieznanski K
Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
[TBL] [Abstract][Full Text] [Related]
8. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
9. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
10. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
Dickey CA; Petrucelli L
Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
[TBL] [Abstract][Full Text] [Related]
11. Dementia Therapy Targeting Tau.
Buee L
Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
[TBL] [Abstract][Full Text] [Related]
12. Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies.
Annadurai N; De Sanctis JB; Hajdúch M; Das V
Exp Neurol; 2021 Sep; 343():113756. PubMed ID: 33989658
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
14. Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.
Dammers C; Yolcu D; Kukuk L; Willbold D; Pickhardt M; Mandelkow E; Horn AH; Sticht H; Malhis MN; Will N; Schuster J; Funke SA
PLoS One; 2016; 11(12):e0167432. PubMed ID: 28006031
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimer's disease and the tauopathies.
Ramachandran G; Udgaonkar JB
Biochemistry; 2013 Jun; 52(24):4107-26. PubMed ID: 23721410
[TBL] [Abstract][Full Text] [Related]
17. [The proceeding of drug development based on the propagation of tau protein].
Suzuki G; Hasegawa M
Nihon Rinsho; 2016 Mar; 74(3):432-7. PubMed ID: 27025082
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation.
Hasegawa M
Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27136595
[TBL] [Abstract][Full Text] [Related]
19. Human Polymerase δ-Interacting Protein 2 (PolDIP2) Inhibits the Formation of Human Tau Oligomers and Fibrils.
Kasho K; Krasauskas L; Smirnovas V; Stojkovič G; Morozova-Roche LA; Wanrooij S
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071254
[TBL] [Abstract][Full Text] [Related]
20. The structure and phase of tau: from monomer to amyloid filament.
Zeng Y; Yang J; Zhang B; Gao M; Su Z; Huang Y
Cell Mol Life Sci; 2021 Mar; 78(5):1873-1886. PubMed ID: 33078207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
